These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 19430406)

  • 1. Costs of the detection of metastases and follow-up examinations in cutaneous melanoma.
    Leiter U; Marghoob AA; Lasithiotakis K; Eigentler TK; Meier F; Meisner C; Garbe C
    Melanoma Res; 2009 Feb; 19(1):50-7. PubMed ID: 19430406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Method of detection of initial recurrence of stage II/III cutaneous melanoma: analysis of the utility of follow-up staging.
    Meyers MO; Yeh JJ; Frank J; Long P; Deal AM; Amos KD; Ollila DW
    Ann Surg Oncol; 2009 Apr; 16(4):941-7. PubMed ID: 19101766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Follow-up recommendations for patients with American Joint Committee on Cancer Stages I-III malignant melanoma.
    Poo-Hwu WJ; Ariyan S; Lamb L; Papac R; Zelterman D; Hu GL; Brown J; Fischer D; Bolognia J; Buzaid AC
    Cancer; 1999 Dec; 86(11):2252-8. PubMed ID: 10590365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methods of detection of first recurrence in patients with stage I/II primary cutaneous melanoma after sentinel lymph node biopsy.
    Moore Dalal K; Zhou Q; Panageas KS; Brady MS; Jaques DP; Coit DG
    Ann Surg Oncol; 2008 Aug; 15(8):2206-14. PubMed ID: 18512102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Melanoma staging: facts and controversies.
    Forschner A; Eigentler TK; Pflugfelder A; Leiter U; Weide B; Held L; Meier F; Garbe C
    Clin Dermatol; 2010; 28(3):275-80. PubMed ID: 20541679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of reduced follow-up in malignant melanoma.
    Hengge UR; Wallerand A; Stutzki A; Kockel N
    J Dtsch Dermatol Ges; 2007 Oct; 5(10):898-907. PubMed ID: 17910672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A rational approach to the follow-up of melanoma patients.
    Garbe C
    Recent Results Cancer Res; 2002; 160():205-15. PubMed ID: 12079215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Follow-up in patients with localised primary cutaneous melanoma.
    Francken AB; Bastiaannet E; Hoekstra HJ
    Lancet Oncol; 2005 Aug; 6(8):608-21. PubMed ID: 16054572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Melanoma costs: a dynamic model comparing estimated overall costs of various clinical stages.
    Alexandrescu DT
    Dermatol Online J; 2009 Nov; 15(11):1. PubMed ID: 19951637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic value of melanoma inhibitory activity serum marker in the follow-up of patients with stage I or II cutaneous melanoma.
    Hofmann MA; Gussmann F; Fritsche A; Biesold S; Schicke B; Küchler I; Voit C; Trefzer U
    Melanoma Res; 2009 Feb; 19(1):17-23. PubMed ID: 19104451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changing trends in melanoma treatment and the expanding role of the dermatologist.
    Brown MD; Johnson TM; Swanson NA
    Dermatol Clin; 1991 Oct; 9(4):657-67. PubMed ID: 1934641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of first relapse in cutaneous melanoma patients: implications for the formulation of evidence-based follow-up guidelines.
    Francken AB; Shaw HM; Accortt NA; Soong SJ; Hoekstra HJ; Thompson JF
    Ann Surg Oncol; 2007 Jun; 14(6):1924-33. PubMed ID: 17357855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective evaluation of a follow-up schedule in cutaneous melanoma patients: recommendations for an effective follow-up strategy.
    Garbe C; Paul A; Kohler-Späth H; Ellwanger U; Stroebel W; Schwarz M; Schlagenhauff B; Meier F; Schittek B; Blaheta HJ; Blum A; Rassner G
    J Clin Oncol; 2003 Feb; 21(3):520-9. PubMed ID: 12560444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cutaneous melanoma: baseline and ongoing laboratory evaluation.
    Garbe C
    Dermatol Ther; 2005; 18(6):413-21. PubMed ID: 16297017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Detection of the first recurrence in patients with melanoma: three quarters by the patient, one quarter during outpatient follow-up].
    Francken AB; Thompson JF; Bastiaannet E; Hoekstra HJ
    Ned Tijdschr Geneeskd; 2008 Mar; 152(10):557-62. PubMed ID: 18402322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Staging work-up and post-treatment surveillance of patients with melanoma.
    Olson JA; Jaques DP; Coit DG; Hwu WJ
    Clin Plast Surg; 2000 Jul; 27(3):377-90, viii. PubMed ID: 10941559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hazard rates for recurrent and secondary cutaneous melanoma: an analysis of 33,384 patients in the German Central Malignant Melanoma Registry.
    Leiter U; Buettner PG; Eigentler TK; Bröcker EB; Voit C; Gollnick H; Marsch W; Wollina U; Meier F; Garbe C
    J Am Acad Dermatol; 2012 Jan; 66(1):37-45. PubMed ID: 21700361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary staging and follow-up in melanoma patients--monocenter evaluation of methods, costs and patient survival.
    Hofmann U; Szedlak M; Rittgen W; Jung EG; Schadendorf D
    Br J Cancer; 2002 Jul; 87(2):151-7. PubMed ID: 12107834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Variations in management of stage I to stage III cutaneous melanoma: a population-based study of clinical practices in France.
    Grange F; Vitry F; Granel-Brocard F; Lipsker D; Aubin F; Hédelin G; Dalac S; Truchetet F; Michel C; Batard ML; Baury B; Halna JM; Schmutz JL; Delvincourt C; Reuter G; Dalle S; Bernard P; Danzon A
    Arch Dermatol; 2008 May; 144(5):629-36. PubMed ID: 18490589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Malignant melanoma: which examinations are useful in staging and follow-up?].
    Goerz G; Schulte-Beerbühl R; Roder K; Schoppe WD; Münchhoff C; Jungblut RM
    Dtsch Med Wochenschr; 1986 Aug; 111(33):1230-3. PubMed ID: 3527640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.